Which strategy is better for resectable synchronous liver metastasis from colorectal cancer, simultaneous surgery, or staged surgery? Multicenter retrospective analysis
- Authors
- Kye, Bong-Hyeon; Lee, Suk-Hwan; Jeong, Woon Kyung; Yu, Chang Sik; Park, In Ja; Kim, Hyeong Rok; Kim, Jin; Lee, In Kyu; Park, Ki-Jea; Choi, Hong-Jo; Kim, Ho Young; Baek, Jeong-Heum; Lee, Yoon-Suk
- Issue Date
- 10월-2019
- Publisher
- KOREAN SURGICAL SOCIETY
- Keywords
- Colorectal neoplasms; Neoplasm metastasis; Surgical oncology
- Citation
- ANNALS OF SURGICAL TREATMENT AND RESEARCH, v.97, no.4, pp.184 - 193
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- ANNALS OF SURGICAL TREATMENT AND RESEARCH
- Volume
- 97
- Number
- 4
- Start Page
- 184
- End Page
- 193
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/62715
- DOI
- 10.4174/astr.2019.97.4.184
- ISSN
- 2288-6575
- Abstract
- Purpose: The optimal treatment for synchronous liver metastasis [LM] from colorectal cancer (CRC) depends on various factors. The present study was intended to investigate the oncologic outcome according to the time of resection of metastatic lesions. Methods: Data from patients who underwent treatment with curative intent for primary CRC and synchronous LM between 2004 and 2009 from 9 university hospitals in Korea were collected retrospectively. One hundred forty-three patients underwent simultaneous resection for primary CRC and synchronous LM (simultaneous surgery group), and 65 patients were treated by 2-stage operation (staged surgery group). Results: The mean follow-up length was 41.2 +/- 24.6 months. In the extent of resection for hepatic metastasis, major hepatectomy was more frequently performed in staged surgery group (33.8% vs. 8.4%, P < 0.0011. The rate of severe complications of Clavien-Dindo classification grade III or more was not significantly different between the 2 groups. The 3-year overall survival (OS) rate was 85.0% in staged surgery group and 69.4% in simultaneous surgery group (P = 0.0131, and the 3-year recurrence-free survival (RFS) rate was 46.4% in staged surgery group and 30.2% in simultaneous surgery group (P = 0.143). In subgroup analysis based on the location of primary CRC, the benefit of staged surgery for OS and RFS was clearly shown in rectal cancer (P = 0.021 and P = 0.015). Conclusion: Based on our results, staged surgery with or without neoadjuvant chemotherapy should be considered for resectable synchronous LM from CRC, especially in rectal cancer, as a safe and fairly promising option.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.